What if there was a treatment that could bring nearly twice as many patients to A1C goal? CLICK HERE to look at the data.
 
Click here to view this e-mail in a browser.
Conference Brief
MedicalEconomics.com

DAY 1 - Sunday, June 26, 2011

Welcome

Greetings from the American Diabetes Association’s 71st Scientific Sessions

The editorial staff of Medical Economics brings you daily coverage of breaking news, the latest research findings, and reports of interest to the readers of Medical Economics, Drug Topics, Formulary, and Contemporary OB/GYN.

Our four-day coverage of this year’s American Diabetes Association’s 71st Scientific Sessions begins today and includes the results of major clinical trials and ongoing news and information of interest to clinicians who treat type 1 and 2 diabetes.

New Research

Toenails clip myth: Mercury in fish is no heart hazard

Sample image

Jane Smith, MD

A study of stored toenail clippings reveals that mercury levels from eating fish pose no heart disease or stroke hazard. Measuring mercury levels in toenails is a good indicator of long-term exposure to mercury from eating fish, according to the investigators.» MORE

Insulin resistance improves with testosterone replacement

Applying a testosterone gel patch daily improves insulin resistance in hypogonadal men with type 2 diabetes and/or metabolic syndrome, found researchers from the United Kingdom.» MORE

Treatment Updates

TIA doubles risk of MI; highest risk is in those younger than 60

A transient ischemic attack (TIA) doubles the risk of myocardial infarction (MI), and this increase in risk persists for several years. Some 456 patients (Mean age: 71 years) who were identified from a medical records database (Rochester Epidemiology Project) as having been diagnosed with a TIA between 1985 and 1994 were followed for a median of 10.2 years. » MORE

Pioglitazone prevents diabetes in impaired glucose tolerance

Sample image

James Jones, MD

Pioglitazone taken prophylactically provided marked protection against the onset of type 2 diabetes in persons at high risk of the disease. In a double-blind study, 602 subjects with impaired glucose tolerance and a body mass index of 25 kg/m2 or greater were randomized to pioglitazone (30 mg/day for the first month, increased to 45 mg/day thereafter) or placebo.» MORE

Breaking News

OTC PPIs not likely to increase fracture risk, says FDA

Short-term use of over-the-counter (OTC) proton pump inhibitors (PPIs) probably does not pose an increased risk for hip, spine, and wrist fractures, according to the U.S. Food and Drug Administration (FDA). In May 2010, the FDA announced that PPI labeling would be revised to include a warning about a possible increased risk of fractures.» MORE

Resistant hypertension may be ‘white coat’ phenomenon

More than one third of patients thought to have resistant hypertension had white-coat hypertension during 24-hour ambulatory monitoring, according to research from the University of Barcelona in Spain.» MORE

Patient Care

Osteoarthritis linked to excess mortality

Patients with hip or knee osteoarthritis (OA) have a higher risk for death than the general population. In a population-based cohort study, Swiss investigators assessed all-cause and disease-specific mortality in 1,163 patients 35 years or older who had symptomatic, radiologically confirmed hip or knee OA.» MORE

Watch for bone loss in adolescents who undergo bariatric surgery

Adolescents who undergo bariatric surgery lose bone in the first 2 years after surgery. Investigators from Children’s Hospital Medical Center in Cincinnati did a retrospective chart review of 61 adolescents (mean age: 17.3 years) who underwent laparoscopic gastric bypass between 2001 and 2008 and had dual-energy radiographic absorptiometry scans before surgery (when possible) and then every 3 to 6 months for 2 years. Whole body bone mineral content (BMC) decreased by 5.2% at the end of 1 year and by 7.4% by 2 years following bariatric surgery.» MORE

Medical Economics is pleased to share this ADA conference coverage with the readers of:

Contemporary OB/GYN(R), Formulary(R), Drug Topics(R)

From the conference floor

MHE image

Picture caption

MHE image

Picture caption

MHE image

Picture caption

MHE image

Picture caption

DISCLAIMER:
This information has been independently developed and provided by the editors of Medical Economics. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
Sample image


Exhibit Hall Hours

Saturday, June 25
10 a.m. – 4 p.m.

Sunday, June 26
10 a.m. – 4 p.m.

Monday, June 27
10 a.m. – 2 p.m.


We welcome your feedback!
Please send your comments to:
Medical Economics editorial staff
[email protected]

 

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.